Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to analyze the multi-omics results between eutopic endometrium, adenomyosis and endometriosis of patients diagnosed of adenomyosis with and without endometriosis. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the pathogenesis of adenomyosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group of adenomyosis | Patients with adenomyosis with or without endometriosis |
| |
| Group of endometriosis | Patients with endometriosis without adenomyosis |
| |
| Group of control | Patients without adenomyosis or endometriosis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A multi-omics analysis | Combination Product | A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium |
|
| Measure | Description | Time Frame |
|---|---|---|
| Frequencies of somatic driving mutations | The differences of distributions and frequencies of somatic driving mutations will be compared between eutopic endometrium and ectopic endometrium by whole exome sequencing. | Two years |
| Measure | Description | Time Frame |
|---|---|---|
| Frequencies of alteration of RNA expression | The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between eutopic endometrium and ectopic endometrium by transcriptome sequencing. | Two years |
| Frequencies of alteration of protein expression and signal pathway |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients with adenomyosis and/or endomtriosis and feasible for biopsy will be included.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lei Li, M.D. | Contact | 13911988831 | 86 | lileigh@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Lei Li, M.D. | Peking Union Medical College Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lei Li | Recruiting | Beijing | Beijing Municipality | 100730 | China |
Not provided
| ID | Term |
|---|---|
| D062788 | Adenomyosis |
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
An 8 ml peripheral venous blood, and 50 μL adenomyosis/endometriosis tissue and tissue adjacent to adenomyosis/endometriosis will be collected from eligible patients.
The alteration of protein expression and signal pathway will be compared between eutopic endometrium and ectopic endometrium by metabolomic sequencing |
| Two years |
| Progression-free survival | Progression-free survival between patients with differential expressed multi-omics will be compared. | Five years |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |